Digital Pharma Lab
Contact
CEESP efficiency opinion: when it is required, what is examined, how to prepare

CEESP efficiency opinion: when it is required, what is examined, how to prepare

What the CEESP efficiency opinion is, when it is required, what the HAS examines in a health-economic model and how to prepare the dossier.

November 18, 2026 · Digital Pharma Lab

The efficiency opinion is the health-economic evaluation issued by the Economic and Public Health Evaluation Committee (CEESP) of the French National Authority for Health (HAS). It is required when the company claims a Clinical Added Value (ASMR) of level I to III and the product is likely to have a significant impact on health insurance expenditure. The opinion does not decide on reimbursement: it informs the price negotiation with the Economic Committee for Health Products (CEPS).

Up to date as of 18 November 2026.

What are the CEESP and the efficiency opinion?

The CEESP is one of the specialised committees of the French National Authority for Health. It assesses health products and strategies from an economic and public health perspective. For a medicine or a medical device, it issues an efficiency opinion: an appraisal of the relationship between the product's costs and health outcomes, compared with those of the alternatives.

This task was entrusted to the HAS by law, then specified by Decree No. 2012-1116 of 2 October 2012 on the health-economic tasks of the French National Authority for Health. The conditions are now set out in article R.161-71-3 of the French Social Security Code, as worded by Decree No. 2018-444 of 4 June 2018 and amended by Decree No. 2020-1090 of 25 August 2020.

The efficiency opinion is distinct from the opinion of the Transparency Committee. The Transparency Committee states whether the medicine brings a clinical benefit and which one (see our article on the transparency dossier); the CEESP states at what cost this benefit is obtained, and with what uncertainty.

When is an efficiency opinion required?

Article R.161-71-3 of the French Social Security Code sets two cumulative conditions:

  1. the company claims a Clinical Added Value (ASMR) of level I, II or III or, for a medical device, an Expected Added Benefit (ASA) of the same level;
  2. the product is likely to have a significant impact on health insurance expenditure, given its effect on the organisation of care, professional practices or patients' conditions of care and, where applicable, its price.

What a "significant impact" covers is specified by HAS board decision No. 2022.0212/DC/SED/SEM of 23 June 2022 (in French), in force since 1 January 2023. For a medicine applying for a first listing, a health-economic evaluation is required in three cases:

  1. the product is an advanced therapy medicinal product (ATMP);
  2. the forecast turnover excluding VAT for the second year of marketing, in the indication concerned, is €20 million or more per year (board decision, art. 1 and 3.1);
  3. the company claims an effect on the organisation of care, professional practices or patients' conditions of care.

The decision provides exceptions for medicines: a product protected by no patent and no supplementary protection certificate, a paediatric indication extension when the adult indication is already reimbursed, an indication extension that increases the population reached by less than 5% at 2 years (board decision, art. 3.2). For a medical device, only the turnover threshold applies. These criteria may change: they should be checked on the date of filing, rather than relying on a value heard during a previous dossier.

In practice, the question arises as soon as the pricing strategy is set. A company aiming for a high ASMR for a high-volume product should plan the health-economic dossier at the same time as the clinical dossier, not afterwards.

What does the CEESP examine in a health-economic model?

The reference framework is the 2020 HAS guide Choices in methods for economic evaluation, available in English. It describes what the committee expects, and deviations are measured against it. The points examined cover the whole construction of the model:

  • the question asked: population, intervention, comparators, outcomes, consistent with the clinical dossier;
  • the comparators: all relevant options in French practice, not only the comparator used in the trials;
  • the type of analysis: cost-utility analysis, which measures outcomes in quality-adjusted life years (QALYs), or cost-effectiveness analysis, depending on what the guide sets for the situation;
  • the perspective, time horizon and discounting, as defined by the guide;
  • the model structure: health states, transitions, extrapolations beyond the duration of the trials;
  • the data: efficacy, safety, utilities and costs, with their sources and their transferability to the French context;
  • the uncertainty analysis: deterministic and probabilistic sensitivity analyses, scenario analyses on the structural assumptions.

A budget impact analysis may also be expected. According to the HAS, it is required in addition to the efficiency analysis for products whose forecast turnover in the second year of marketing exceeds €50 million excluding VAT, under the framework agreement between the CEPS and Leem (Understanding the economic evaluation of health products, in French). The HAS devotes a separate methodological guide to it (in French).

How to read an efficiency opinion?

The opinion first addresses the method. The committee records deviations from the guide as reservations, rated minor, important or major depending on their effect on the conclusions. According to the CEESP doctrine (in French), a major reservation invalidates all or part of the economic evaluation.

The opinion then addresses the result: the incremental cost-effectiveness ratio (ICER, RDCR in French), that is, the additional cost per unit of outcome gained, for example per QALY, against each comparator. The committee discusses this ratio in light of the uncertainty surrounding it, and specifies the assumptions that make it vary the most.

France does not publish an official threshold above which a product would be considered not cost-effective. The ratio is read in context: severity of the disease, medical need, robustness of the data.

The opinion is sent to the CEPS, which takes it into account in the price negotiation. It is also published by the HAS, which makes it a reference for subsequent dossiers in the same therapeutic area.

How to prepare?

Preparing a health-economic dossier follows a logic close to that of the clinical dossier, with its own requirements:

  1. anticipate from phase II: collect quality-of-life data usable for utilities, and identify French cost sources;
  2. frame the question with the same comparators and population as the Transparency Committee dossier;
  3. build the model according to the HAS guide, documenting each deviation and its rationale;
  4. trace each assumption: its source, its justification, its effect on the result;
  5. test uncertainty thoroughly, including survival extrapolations and utilities;
  6. write for a demanding reviewer: a clear technical report, a readable and reproducible model;
  7. prepare the exchanges with the HAS staff during the review, whose arrangements the HAS describes on its website.

What are the most common mistakes?

The opinions published by the CEESP highlight reservations that come up often:

  • one or more relevant comparators missing from the analysis;
  • survival extrapolated beyond the trials without justification or alternative scenarios;
  • utilities derived from an ill-suited population or instrument;
  • costs that do not reflect the care pathway in France;
  • inconsistency between the model and the clinical dossier, for example on the population or the duration of effect;
  • an incomplete uncertainty analysis, which leaves aside the assumptions that weigh the most;
  • a model too opaque for the experts to review and rerun the calculations.

Each of these reservations is easier to address when the model is designed than when responding to the opinion.

Where to start?

Start by checking whether your product falls within the scope of the efficiency opinion, in light of the two conditions of the code and the HAS decision in force. Then reread the methodological guide and two or three recent CEESP opinions in your therapeutic area: they show concretely what the committee accepts and what it challenges.

Health economics is prepared together with the rest of the access strategy: transparency dossier, possible early access, and a measured use of AI for literature reviews or model documentation, which we describe in what AI changes in market access.

This article provides general information; it does not replace regulatory advice tailored to your product. For support in building a model or preparing a dossier, discover our market access expertise.

Sources

Sources accessed on 18 November 2026.

Our expertise on this topic

  • Market Access

    Building robust access strategies, solid health-economic evaluations, and HAS dossiers that withstand scrutiny.